Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 51-75 of 127 citing articles:

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
Mark Lebwohl, Andrew Blauvelt, Alan Menter, et al.
American Journal of Clinical Dermatology (2019) Vol. 20, Iss. 6, pp. 863-871
Open Access | Times Cited: 35
The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Markus Joerger, Stephen P. Finn, Sinéad Cuffe, et al.
Expert Opinion on Therapeutic Targets (2016) Vol. 20, Iss. 11, pp. 1339-1356
Closed Access | Times Cited: 34
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
Michael Roman, Melvin Chiu
Drug Design Development and Therapy (2017) Vol. Volume 11, pp. 2065-2075
Open Access | Times Cited: 34
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials
Bénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
RMD Open (2019) Vol. 5, Iss. 1, pp. e000763-e000763
Open Access | Times Cited: 34
Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis
Logan W Thomas, Erica B. Lee, Jashin J. Wu
Journal of Dermatological Treatment (2018) Vol. 30, Iss. 2, pp. 110-116
Closed Access | Times Cited: 33
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.
Daniela Mikhaylov, Peter W. Hashim, Tatyana Nektalova, et al.
PubMed (2019) Vol. 12, Iss. 6, pp. 46-54
Closed Access | Times Cited: 32
Brodalumab: A new way to inhibit IL ‐17 in psoriasis
Paola Facheris, Mario Valenti, Giulia Pavia, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 30
Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review
Jessica E. Ferguson, Edward W. Seger, Jacob White, et al.
Archives of Dermatological Research (2022) Vol. 315, Iss. 1, pp. 41-50
Closed Access | Times Cited: 18
Brodalumab in plaque psoriasis: Real‐world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks
Natalia Rompoti, Maria Politou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4, pp. 689-697
Closed Access | Times Cited: 18
Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis
Guomei Xu, Meng Xia, Chenjie Jiang, et al.
Journal of Pharmacological Sciences (2018) Vol. 139, Iss. 4, pp. 289-303
Open Access | Times Cited: 31
Brodalumab for the treatment of psoriasis
Marco Galluzzo, S. D’Adamio, Luca Bianchi, et al.
Expert Review of Clinical Immunology (2016) Vol. 12, Iss. 12, pp. 1255-1271
Closed Access | Times Cited: 27
Gastroenterological safety of IL-17 inhibitors: a systematic literature review
Bénédicte Caron, Jean‐Yves Jouzeau, Pierre Miossec, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 2, pp. 223-239
Closed Access | Times Cited: 23
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
Alan Menter, Tina Bhutani, Benjamin D. Ehst, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1289-1302
Open Access | Times Cited: 14
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries
Jui Vyas, Jeffrey Johns, F.M. Ali, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 3, pp. 315-339
Open Access | Times Cited: 8
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Journal of Psoriasis and Psoriatic Arthritis (2018) Vol. 4, Iss. 1, pp. 31-58
Open Access | Times Cited: 25
Brodalumab: First Global Approval
Sarah L. Greig
Drugs (2016) Vol. 76, Iss. 14, pp. 1403-1412
Closed Access | Times Cited: 24
<p>Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date</p>
Marco Galluzzo, S. D’Adamio, Antonio Massaro, et al.
Clinical Cosmetic and Investigational Dermatology (2019) Vol. Volume 12, pp. 311-321
Open Access | Times Cited: 24
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis
Shanshan Xu, Xing Gao, Jixiang Deng, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2020) Vol. 19, Iss. 1, pp. 47-56
Closed Access | Times Cited: 22
Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
Ulrich Mrowietz, Richard B. Warren, C. Leonardi, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 5, pp. 1161-1175
Open Access | Times Cited: 19
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review
Elisa Camela, Sonia Sofìa Ocampo‐Garza, Eleonora Cinelli, et al.
Dermatologic Therapy (2021) Vol. 34, Iss. 2
Open Access | Times Cited: 18
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2637-2644
Open Access | Times Cited: 7
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions
Kevin C.‐W. Wu, Michael P. Lee, Erica B. Lee, et al.
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 4, pp. 359-365
Closed Access | Times Cited: 21
Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
Kyle Fahrbach, Grammati Sarri, David Phillippo, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 6, pp. 1965-1998
Open Access | Times Cited: 16
Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study
Shinichi Imafuku, Chika Ohata, Yukari Okubo, et al.
Journal of Dermatological Science (2022) Vol. 105, Iss. 3, pp. 176-184
Closed Access | Times Cited: 12
Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
Yuliya Lytvyn, Muskaan Sachdeva, Asfandyar Mufti, et al.
Drugs in Context (2022) Vol. 11, pp. 1-12
Open Access | Times Cited: 11

Scroll to top